Resources
[MediRama EDGE] TUDRIQEV: from FDA CRLs to Accelerated Approval
- Writer:관리자
- Date:2026-10-07
Through the development and approval journey of Tudriqev, we explore key considerations in building clinical evidence for novel modalities, addressing FDA concerns, demonstrating therapeutic value with limited data, and developing effective regulatory strategies for Accelerated Approval.